DTC Genomics Firms Say They Want to Comply with FDA Regs but Maintain Direct Access
March 16, 2011
DTC Genomics Firms Say They Want to Comply with FDA Regs but Maintain Direct Access
At an advisory committee meeting held this week to discuss how FDA should regulate DTC genomics firms, several companies said that they are willing to meet the agency's clinical and analytical validity requirements, but will push to maintain direct-to-consumer marketing for their products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Tells Congress it is Mulling Strategies to Regulate DTC Genetic Tests as Medical Devices
July 28, 2010 / Pharmacogenomics Reporter - DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy
July 21, 2010 / Pharmacogenomics Reporter - As Congress Investigates DTC Genomics Market, Firms Vow Cooperation
May 26, 2010 / Pharmacogenomics Reporter - FDA's Gutierrez Provides Additional Clarity Regarding Oversight of DTC Genomics Firms
May 19, 2010 / Pharmacogenomics Reporter - Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter